COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE

被引：1
|
作者：
Charokopou, M. [1 ]
Chuang, L. [1 ]
Verheggen, B. [1 ]
Gibson, D. [2 ]
Grandy, S. [3 ]
Kartman, B. [4 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] AstraZeneca, Luton, Beds, England
[3] Astrazeneca Pharmaceut LP, Gaithersburg, MD USA
[4] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2090
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB50
引用
收藏
页码：A606 / A606
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
    Chuang, L. H.
    Verheggen, B. G.
    Charokopou, M.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1127 - 1134
  • [2] Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
    Peter Gæde
    Pierre Johansen
    Christian Klyver Tikkanen
    Richard Fulton Pollock
    Barnaby Hunt
    Samuel Joseph Paul Malkin
    Diabetes Therapy, 2019, 10 : 1297 - 1317
  • [3] Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
    Gaede, Peter
    Johansen, Pierre
    Tikkanen, Christian Klyver
    Pollock, Richard Fulton
    Hunt, Barnaby
    Malkin, Samuel Joseph Paul
    DIABETES THERAPY, 2019, 10 (04) : 1297 - 1317
  • [4] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [5] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
  • [6] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [7] The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
    Wang, Bruce
    Roth, Joshua A.
    Nguyen, Hiep
    Felber, Eugene
    Furnback, Wes
    Garrison, Louis P.
    PLOS ONE, 2015, 10 (04):
  • [8] A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
    Johansen, Pierre
    Sandberg, Anna
    Capehorn, Matthew
    ADVANCES IN THERAPY, 2020, 37 (03) : 1248 - 1259
  • [9] A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
    Pierre Johansen
    Anna Sandberg
    Matthew Capehorn
    Advances in Therapy, 2020, 37 : 1248 - 1259
  • [10] Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden
    Ericsson, Asa
    Fridhammar, Adam
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 997 - 1005
12345